Slide 1: RECLAIM Phase 2 Trial in AUD Topline Results
RECLAIM Phase 2 Trial in AUD Topline Results July 28, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements
Slide 3: Pemvidutide
Pemvidutide Glucagon/GLP-1 Dual Receptor Agonist with 1:1 Balanced Potency COOH Pemvidutide (CH2)n EuPort EuPort Domain Delayed Tmax with lower Cmax† Designed to Increase Tolerability Glucagon specificity GLP-1 specificity Direct impact on the liver and metabolism Direct impact on GI and CNS Pem
Slide 4: RECLAIM Phase 2 AUD Trial Design
RECLAIM Phase 2 AUD Trial Design A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Patients with Obesity or Overweight Screening/Randomization 1:1 1.2 mg 1.8 mg 2.4 mg weekly
Slide 5: RECLAIM Phase 2 AUD Trial Patient Disposition
RECLAIM Phase 2 AUD Trial Patient Disposition 100 Randomized Placebo Pemvidutide 2.4 mg N=50 N=50 11 Discontinued Treatment 10 Discontinued Treatment 9 Withdrawal by Subject 6 Adverse Event 6 lack of efficacy 3 Withdrawal by Subject 1 relapse 2 schedule conflict 1 personal reasons 1 no longer wanted
Slide 6: Balanced Baseline Demographics and Disease Characteristics
Balanced Baseline Demographics and Disease Characteristics Placebo Pemvidutide Characteristic (N=50) (N=50) Age, years (SD) 50.0 (10.0) 50.8 (11.9) Female sex, n (%) 26 (52) 26 (52) Body weight, kg (SD) 96.0 (21.4) 92.0 (19.1) BMI, kg/m2 (SD) 32.5 (6.6) 32.3 (5.8) AUD by DSM-5, n (%) Moderate (4–5 s
Slide 7: Pemvidutide Achieved Significantly Greater Reduction in Heavy Drinking Days/Week Compared to Placebo
Pemvidutide Achieved Significantly Greater Reduction in Heavy Drinking Days/Week Compared to Placebo Heavy Drinking Days (HDD) Met Primary Endpoint Treatment difference at Week 24: -1.45 HDD/week (p = 0.0014) * p = 0.0014 vs. placebo (MMRM) LSM: Least Squares Mean ; MMRM = Mixed model repeated measu
Slide 8: Significantly Greater Percentage of Pemvidutide Patients Achieved 2-level Reduction in WHO Risk Drinking Levels
Significantly Greater Percentage of Pemvidutide Patients Achieved 2-level Reduction in WHO Risk Drinking Levels (RDL) Patients Achieving 2-Level Reduction in WHO-RDL from Baseline A 2-level reduction in WHO-RDL is an FDA registrational endpoint ~2/3 of pemvidutide patients achieved a 2-level reducti
Slide 9: Significantly More Pemvidutide Patients Achieved Zero Heavy Drinking Days Compared to Placebo
Significantly More Pemvidutide Patients Achieved Zero Heavy Drinking Days Compared to Placebo Patients Achieving Zero Heavy Drinking Days Zero Heavy Drinking Days is an FDA registrational endpoint The percentage of pemvidutide patients achieving Zero Heavy TheDrinking days was more than twice that o
Slide 10: Pemvidutide Showed A Significant Increase in Percentage of Days with Abstinence
Pemvidutide Showed A Significant Increase in Percentage of Days with Abstinence Compared to Placebo Percent of Days With Drinking Abstinence Significant increase in Percent of Days with Abstinence compared to placebo at Week 24 * p = 0.0075 vs. placebo (MMRM) 10
Slide 11: Pemvidutide Showed a Significant Reduction in Serum PEth Levels
Pemvidutide Showed a Significant Reduction in Serum PEth Levels – an Objective Measure of Recent Alcohol Use Serum PEth Levels PEth (phosphatidylethanol) is a serum marker of recent alcohol intake Treatment difference compared to placebo at Week 24 = -175.3 ng/mL, p <0.0001 * p < 0.0001 vs. placebo
Slide 12: Pemvidutide Showed Significant and Continuing Weight Loss
Pemvidutide Showed Significant and Continuing Weight Loss Weight Loss Treatment difference from placebo at Week 24 = -9.1% Weight loss continuing at 24 weeks * p < 0.0001 vs. placebo (MMRM) 12
Slide 13: Pemvidutide
Pemvidutide Glucagon/GLP-1 Dual Receptor Agonist with 1:1 Balanced Potency Pemvidutide may address both the excessive drinking of AUD and the negative effects it has on the liver COOH Pemvidutide (CH2)n EuPort EuPort Domain Delayed Tmax with lower Cmax† Designed to Increase Tolerability Glucagon
Slide 14: Numerically Greater Improvement in FIB-4 Status in Patients with Baseline FIB-4 ≥ 1.3
Numerically Greater Improvement in FIB-4 Status in Patients with Baseline FIB-4 ≥ 1.3† (Exploratory Analysis) Reduction in FIB-4 to < 1.3 FIB-4 Index is a prognostic marker of liver fibrosis † EASL defines FIB-4 < 1.3 in alcohol- related liver disease (ALD) as low risk of advanced fibrosis†† †p = 0.
Slide 15: Safety Profile
Safety Profile Majority of AEs Mild to Moderate in Severity Pemvidutide Data are presented as n (%). Placebo 2.4 mg (N=50) (N=50) Serious AEs 1 (2%)† 2 (4%)†† Serious AEs related to study med 0 (0%) 1 (2%) Severe AEs 3 (6%) 6 (12%) Severe AEs related to study med 0 (0%) 3 (6%)‡ AEs of Special Intere
Slide 16: Safety Profile
Safety Profile Gastrointestinal (GI) AEs Mostly Mild to Moderate in Severity Pemvidutide GI Adverse Events (Data are presented as n (%) Placebo 2.4 mg (N=50) (N=50) Nausea 12 (24%) 22 (44%) Vomiting 3 (6%) 9 (18%) Diarrhea 5 (10%) 10 (20%) Constipation 3 (6%) 13 (26%) 16
Slide 17: Summary: Positive RECLAIM Topline Results in AUD
Summary: Positive RECLAIM Topline Results in AUD Pemvidutide met the primary and important secondary endpoints, including the two recognized by the FDA as registrational endpoints for AUD (2-level reduction in WHO-RDL and Zero Heavy Drinking Days) Pemvidutide showed a generally favorable tolerabilit
Slide 18: Advancing Pemvidutide Programs
Advancing Pemvidutide Programs AUD • Delivered positive topline data from RECLAIM Phase 2 trial and • Plan to request an End-of-Phase 2 meeting with FDA Metabolic Dysfunction-Associated Steatohepatitis (MASH) • Initiate PERFORMA Phase 3 trial in 3Q26 Alcohol-Associated Liver Disease (ALD) • Complete
Slide 19: Thank you
altimmune - ia